Description
While TREM2 was identified as a critical microglial checkpoint, the specific molecular mechanisms linking TREM2 variants to microglial dysfunction were not elucidated. This mechanistic gap prevents rational drug design for TREM2-targeted therapies.
Source: Debate session sess_SDA-2026-04-03-gap-seaad-20260402025452 (Analysis: SDA-2026-04-03-gap-seaad-20260402025452)
Resolution criteria
Resolution requires: (1) phosphoproteomics of microglia from TREM2 loss-of-function AD patients vs controls (n>=10 per group), identifying downstream signaling cascades (Syk, BTK, MAPK, PI3K/AKT) with >=2-fold alteration in patient samples; (2) targeted metabolomics or lipidomics of TREM2-variant microglia showing lipid metabolic dysregulation; (3) rescue experiments in iPSC-derived microglia with TREM2 variants using TREM2 agonists or downstream pathway activators, demonstrating which pathway disruption is most therapeutically actionable with rescue efficiency >=50%. Identifying pathway components without functional validation in human cells is insufficient.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:20.797876+00:00”, “resolution_summary”: “Resolved by hypothesis h-d083850487: TREM2-dependent microglial phagocytosis of tau seeds. Supporting evidence includes debate sess_SDA-2026-04-15-gap-debate-20260410-112400-454036f1_20260416-035530.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-d083850487”, “title”: “TREM2-dependent microglial phagocytosis of tau seeds”, “score”: 0.447, “reason”: “6 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-2026-04-26-gap-pubmed-20260410-150544-e3a2eab9-debate”, “target_gene”: “TREM2/Syk/PLCγ2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.53, “confidence_score”: 0.5, “status”: “proposed”, “pubmed_evidence_ids”: [“26653636”, “29518356”, “29689295”, “36306735”, “36564824”]}, {“id”: “h-var-47bbbf5711”, “title”: “TREM2-Dependent Astrocyte-Microglia Cross-talk in Neuroinflammation”, “score”: 0.396, “reason”: “10 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-BIOMNI-SPATIAL_-c2b61633”, “target_gene”: “TREM2”, “target_pathway”: “TREM2/astrocyte-microglia cross-talk → neuroinflammation”, “disease”: “neurodegeneration”, “composite_score”: 0.38, “confidence_score”: 0.715, “status”: “promoted”, “pubmed_evidence_ids”: [“20301376”, “24047521”, “28802038”, “30258234”, “31932797”]}, {“id”: “h-analogy-ceb122df”, “title”: “TREM2-complement-amyloid axis as therapeutic target for protein aggregation disorders”, “score”: 0.393, “reason”: “10 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: null, “target_gene”: “TREM2”, “target_pathway”: “TREM2-complement-amyloid axis”, “disease”: “unknown”, “composite_score”: 0.55, “confidence_score”: 0.45, “status”: “active”, “pubmed_evidence_ids”: []}, {“id”: “h-44b1c9d415”, “title”: “TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease”, “score”: 0.392, “reason”: “7 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “legacy-pre-pipeline-import-v1”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.827427, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“26741508”, “28165511”, “29196612”]}, {“id”: “h-a3a1a15a56”, “title”: “Butyrate-Producing Commensal Depletion Creates Vicious Cycle: HDAC3 Overactivity Permits TREM2-Independent Microglial Dysfunction”, “score”: 0.39, “reason”: “6 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-2026-04-26-gap-20260425-225305”, “target_gene”: “HDAC3, TREM2, PGC-1α, NLRP3, HIF1α”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.63, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“25472853”, “27523554”, “31277771”, “33208957”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-debate-20260410-112400-454036f1_20260416-035530”, “title”: “The debate revealed contradictory evidence about CD8+ T cell roles in neurodegeneration, with some studies showing protection and others showing harm. This fundamental mechanistic uncertainty prevents rational immune-targeting therapies.\n\nSource: Debate session sess_SDA-2026-04-03-gap-aging-mouse-brain-v2-20260402 (Analysis: SDA-2026-04-03-gap-aging-mouse-brain-v2-20260402)”, “score”: 0.455, “reason”: “9 token overlaps; entity overlap: sda-2026-04-03-”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112400-454036f1”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-112430-676f2b59”, “title”: “The debate raised conflicting views on whether myelin restoration would be beneficial or harmful in AD. The skeptic suggested myelin loss could be adaptive to reduce metabolic burden, but this fundamental question remains unresolved and is critical for oligodendrocyte-targeted therapies.\n\nSource: Debate session sess_SDA-2026-04-03-gap-seaad-20260402025452 (Analysis: SDA-2026-04-03-gap-seaad-20260402025452)”, “score”: 0.425, “reason”: “9 token overlaps; entity overlap: sda-2026-04-03-”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-112430-676f2b59”, “quality_score”: 1.0, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f”, “title”: “While TREM2 was identified as critical for microglial senescence, the debate lacked fine-grained temporal data on when and how TREM2 signaling shifts from neuroprotective to pathogenic. Understanding this transition timing is essential for intervention strategies.\n\nSource: Debate session sess_SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402 (Analysis: SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402)”, “score”: 0.412, “reason”: “8 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f”, “quality_score”: 0.73, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-112348-d9e9b948”, “title”: “The debate proposed temporal TFEB modulation but identified no validated biomarkers to guide when TFEB should be enhanced versus inhibited. This represents a critical gap preventing clinical implementation of stage-specific TFEB therapies.\n\nSource: Debate session sess_SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc (Analysis: SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc)”, “score”: 0.406, “reason”: “8 token overlaps; entity overlap: sda-2026-04-03-”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-112348-d9e9b948”, “quality_score”: 1.0, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-112343-6340ce52”, “title”: “The debate identified that ketone levels >2.0 mM may disrupt astrocyte-neuron metabolic coupling, but the precise dose-response relationship remains undefined. This critical gap prevents safe therapeutic implementation of ketogenic interventions.\n\nSource: Debate session sess_SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 (Analysis: SDA-2026-04-03-gap-debate-20260403-222618-2709aad9)”, “score”: 0.401, “reason”: “8 token overlaps; entity overlap: sda-2026-04-03-”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-112343-6340ce52”, “quality_score”: 1.0, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}